| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Temocapril (CS-622; CS622; temocaprilum; Aceco) is a potent and long-acting angiotensin-converting enzyme (ACE) inhibitor, approved for use (not in the USA) in the treatment of hypertension. Temocapril is a prodrug-type of ACE inhibitor not approved for use in the United States, but was approved in Japan and South Korea. Temocapril can also be used in hemodialysis patients without risk of serious accumulation.
| ln Vitro |
The prodrug of Temocaprilat, an ACE inhibitor, is Temocapril hydrochloride. Temoprilat hydrochloride is easily absorbed by the small intestine and then processed by CES1 (human carboxylesterase 1) in the liver to produce its active metabolite, temoprilat [1]. In spontaneously hypertensive rats (SHR), temocapril hydrochloride (500 nM) lessens the inhibitory effects of RS (N-acetyltetradecane renin substrate) and AngI (angiotensin) on neurogenic vasodilation [2]. The redox protein thioredoxin (TRX) is stimulated by temocapril hydrochloride (0.1–10 μM; 24 h), although the expression of the antioxidant enzymes Cu/ZnSOD and Mn-SOD is unaffected [3].
|
|---|---|
| ln Vivo |
In addition to improving autoimmune myocarditis, temocapril (10 mg/kg; oral; 21 days) increases the expression of thioredoxin in cardiomyocytes [3]. Temocapril (30 mg/kg; oral; once daily; for 4 weeks) did not lower renal Ang II levels but does suppress angiotensin I-induced hypertension, plasma, and renal ACE activity [4].
|
| Cell Assay |
Western Blot analysis [3]
Cell Types: Cultured neonatal rat cardiomyocytes Tested Concentrations: 0.1 μM, 1 μM, 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: The expression of redox protein thioredoxin (TRX) was enhanced by 1.9 times at 10 μM , and does not affect TRX2, Cu/Zn-SOD or Mn-SOD protein expression. |
| Animal Protocol |
Animal/Disease Models: Experimental autoimmune myocarditis (EAM) rat model [3]
Doses: 10 mg/kg Route of Administration: po (oral gavage); water management; 21-day Experimental Results: Improve EAM and prevent cellular protein oxidation. The expression of redox regulatory protein TRX in cardiomyocytes is enhanced. Animal/Disease Models: Male Sprague Dawley rat [4] Doses: 30 mg/kg Route of Administration: po (oral gavage), one time/day for 4 weeks. Experimental Results: Inhibited the increase in blood pressure caused by Ang I. |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Temocapril is rapidly absorbed in the gastrointestinal tract and converted into the diacid (active) metabolite, which inhibits ACE in plasma. Temocapril is eliminated primarily through the liver and kidneys. 19.4% urinary recovery. Biological Half-Life 13.1 hours in patients with normal liver function. |
| Toxicity/Toxicokinetics |
Protein Binding
99.5%, including those with renal impairment. |
| References |
|
| Additional Infomation |
Temocapril is a dipeptide.
Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea. Temocapril can also be used in hemodialysis patients without risk of serious accumulation. Drug Indication Temocapril is an ACE inhibitor primarily indicated in the treatment of hypertension and congestive heart failure, diabetic nephropathy, and improvement of prognosis for coronary artery diseases (including acute myocardial infarction). Pharmacodynamics Temocapril is a prodrug of its active metabolite (and diacid form) temocaprilat which contains a thiazepine ring. Temocaprilat has slightly higher potency than enalaprilat in ACE inhibition isolated from rabbit lung. ACE inhibitors exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.). When compared with other Angiotensin-converting Enzyme Inhibitors, temocapril's advantages include a rapid onset of action and what research suggests is tighter vascular ACE binding than enalaprilat. |
| Molecular Formula |
C23H28N2O5S2
|
|
|---|---|---|
| Molecular Weight |
476.61
|
|
| Exact Mass |
476.144
|
|
| CAS # |
111902-57-9
|
|
| Related CAS # |
Temocapril hydrochloride;110221-44-8;Temocapril-d5;1356840-03-3
|
|
| PubChem CID |
443874
|
|
| Appearance |
Off-white to yellow solid powder
|
|
| Density |
1.33 g/cm3
|
|
| Boiling Point |
717.4ºC at 760 mmHg
|
|
| Melting Point |
>230ºC (dec)
|
|
| Flash Point |
387.7ºC
|
|
| LogP |
3.3
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
8
|
|
| Rotatable Bond Count |
11
|
|
| Heavy Atom Count |
32
|
|
| Complexity |
644
|
|
| Defined Atom Stereocenter Count |
3
|
|
| SMILES |
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(C2=O)CC(=O)O)C3=CC=CS3
|
|
| InChi Key |
FIQOFIRCTOWDOW-BJLQDIEVSA-N
|
|
| InChi Code |
InChI=1S/C23H28N2O5S2/c1-2-30-23(29)17(11-10-16-7-4-3-5-8-16)24-18-15-32-20(19-9-6-12-31-19)13-25(22(18)28)14-21(26)27/h3-9,12,17-18,20,24H,2,10-11,13-15H2,1H3,(H,26,27)/t17-,18-,20-/m0/s1
|
|
| Chemical Name |
2-[(2S,6R)-6-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-5-oxo-2-thiophen-2-yl-1,4-thiazepan-4-yl]acetic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0982 mL | 10.4908 mL | 20.9815 mL | |
| 5 mM | 0.4196 mL | 2.0982 mL | 4.1963 mL | |
| 10 mM | 0.2098 mL | 1.0491 mL | 2.0982 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA